Investigation of pain relief and side effects of 186Re-HEDP in patients with widespread bone metastasis

Introduction: Rhenium-186-HEDP (186Re-HEDP), a new and attractive radiopharmaceutical for the treatment of bone pain due to metastases, is produced recently by Iranian Atomic Energy organization (IAEO, IR .Iran). The aim of this study is to investigate palliative and side effect of 186 Re- HEDP in patients with different types of cancers. Methods: Nineteen (8 male, 11 female) patients with various cancers (breast, prostate, RCC, colon, NET) and bone metastases were included in the study and 40-100 mci 186 Re-HEDP was administered slowly. The patients with bone marrow suppression, pathologic fracture or cord compression were excluded from the study. The pain relief was assessed by Visual Analogue Scale (VAS), for 8 weeks after treatment. Blood sample were taken weekly in this period. Results: no side effect was reported by the patients during injection and 4-6 hours after administration. Flare reaction was seen in 63.2% of patients. Palliation effect is seen in 48-72 hr after treatment in responders. The maximal palliation was observed between 1-3 weeks. Overall response rate was 89.5%. Mean pain score (VAS) was decreased from 9.1 to 5.3 after 1 week and 6.63 after 8th week. (P< effects side minimal shows and pain bone metastatic of treatment palliative the in used radiopharmaceutical effective an is Re-HEDP 186. Conclusion: hemoglobin. serum seen change significant No toxicity. marrow 4 grade revealed patient treatment. after weeks Th 6 ml 5941 to 11270 from count lymphocyte mean.